Enanta Q2 net loss narrows to $22.6M; RSV study enrollment target met

ENANTA PHARMACEUTICALS INC

2025-Q2 EPS reported -$2.11 vs consensus -$1.30 ▼ miss (-62.1%)

Revenue $14.9M, down 13% YoY from $17.1M; net loss $22.6M ($1.06 loss per share) vs $31.2M ($1.47) in prior year.
Cash and marketables $193.4M at March 31; plus $33.8M tax refund in April; expects runway into fiscal 2028.
Phase 2 RSVHR study of zelicapavir met enrollment target of 180 high-risk adults; topline data expected late Q3 2025.
STAT6 program: plan to select development candidate in 2H 2025; KIT inhibitor EPS-1421 IND-enabling studies ongoing.
Filed opening brief in patent infringement appeal against Pfizer over Paxlovid; original case filed June 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.